Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
...
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers
- Conditions
- First Posted Date
- 2011-05-10
- Last Posted Date
- 2012-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT01350921
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
- Conditions
- Interventions
- First Posted Date
- 2011-05-04
- Last Posted Date
- 2015-07-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1875
- Registration Number
- NCT01347580
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)
- Conditions
- Interventions
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 801
- Registration Number
- NCT01294462
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2010-05-06
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 146
- Registration Number
- NCT01118325
- Locations
- 🇵🇭
Research Site, Quezon City, Philippines
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
- Conditions
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 98
- Registration Number
- NCT00642811
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18624
- Registration Number
- NCT00391872
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.